90y-dota-epratuzumab
mAbexperimentalADC
Clinical trial activity
2 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2007 (NCT00906841)
Timeline
Indications
Mechanism of action
- CD22INHIBITOR
CD22 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
- Payload
- 90-Yttrium
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108666 ↗
Also known as
- 90y-dota-epratuzumab
- 90y-dota-hll2
- 90y-dota-hll2
- yttrium y 90 epratuzumab tetraxetan
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02577094 | Phase 1/Phase 2 (Phase 2) | Oct 2, 2015 | Immunomedics, Institut de Cancerologie de l'Ouest Paul Papin, University of Nantes |
| NCT00906841 | Phase 2 | Oct 1, 2007 | French Innovative Leukemia Organisation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| French Innovative Leukemia Organisation | Academic/Hospital | 1 | 1 | 1 | 2007 |
| Immunomedics | For profit | 1 | 0 | 1 | 2015 |
| Institut de Cancerologie de l'Ouest Paul Papin | Academic/Hospital | 1 | 0 | 1 | 2015 |
| University of Nantes | Academic/Hospital | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1